4.8 Article

Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum

期刊

NATURE
卷 480, 期 7378, 页码 534-U158

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nature10606

关键词

-

资金

  1. Wellcome Trust [077108, 089084]
  2. National Institutes of Health [R01AI057919]
  3. Center for Disease Control [R36 CK000119-01]
  4. Epidemiology of Infectious Disease and Biodefense Training Grant [2T32 AI007535-12]
  5. MRC [G19/9] Funding Source: UKRI
  6. Medical Research Council [G0600718B, G19/9] Funding Source: researchfish

向作者/读者索取更多资源

Erythrocyte invasion by Plasmodium falciparum is central to the pathogenesis of malaria. Invasion requires a series of extracellular recognition events between erythrocyte receptors and ligands on the merozoite, the invasive form of the parasite. None of the few known receptor-ligand interactions involved(1-4) are required in all parasite strains, indicating that the parasite is able to access multiple redundant invasion pathways(5). Here, we show that we have identified a receptor-ligand pair that is essential for erythrocyte invasion in all tested P. falciparum strains. By systematically screening a library of erythrocyte proteins, we have found that the Ok blood group antigen, basigin, is a receptor for PfRh5, a parasite ligand that is essential for blood stage growth(6). Erythrocyte invasion was potently inhibited by soluble basigin or by basigin knockdown, and invasion could be completely blocked using low concentrations of anti-basigin antibodies; importantly, these effects were observed across all laboratory-adapted and field strains tested. Furthermore, Ok(a-) erythrocytes, which express a basigin variant that has a weaker binding affinity for PfRh5, had reduced invasion efficiencies. Our discovery of a cross-strain dependency on a single extracellular receptor-ligand pair for erythrocyte invasion by P. falciparum provides a focus for new anti-malarial therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据